S 2E

Drug Profile

S 2E

Latest Information Update: 15 Mar 2007

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antihyperlipidaemics
  • Mechanism of Action Cholesterol inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 20 Oct 1998 A study has been added to the Hyperlipidaemia pharmacodynamics section
  • 20 Oct 1998 Preclinical development for Hyperlipidaemia in Japan (Unknown route)
  • 20 Jul 1998 No-Development-Reported for Hyperlipidaemia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top